Edition:
India

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

176.49USD
20 Jul 2018
Change (% chg)

$-0.62 (-0.35%)
Prev Close
$177.11
Open
$177.10
Day's High
$177.28
Day's Low
$175.00
Volume
103,593
Avg. Vol
182,868
52-wk High
$183.96
52-wk Low
$128.58

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $8,797.71
Shares Outstanding(Mil.): 60.06
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 22.31 30.93 32.76
EPS (TTM): 6.57 -- --
ROI: 10.38 15.07 14.61
ROE: 20.73 16.60 16.34

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

13 Jul 2018

UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

13 Jul 2018

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

13 Jul 2018

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

09 May 2018

UPDATE 2-Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

09 May 2018

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals plc on Tuesday said that it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

09 May 2018

BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

30 Apr 2018

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

02 Mar 2018

Earnings vs. Estimates